Table 2.

Distribution of the positive status for the 13 studied autoantibodies

Autoantibodies	SLE patients from Sweden n=723 [%]	SLE patients from Ohio, USA n=188 [%]
Anti‐DNA	218 [30.15]	41 [21.81]
Anti‐nucleosome	273 [37.76]	48 [25.53]
Anti‐ribosomal P	40 [5.56]	12 [6.38]
Anti‐RNP68	59 [8.19]	9 [4.79]
Anti‐RNPA	162 [22.50]	27 [14.36]
Anti‐Sm	105 [14.58]	20 [10.64]
Anti‐SmRNP	159 [22.08]	29 [15.43]
Anti‐SSA/Ro52	204 [28.33]	37 [19.68]
Anti‐SSA/Ro60	293 [40.69]	48 [25.53]
Anti‐SSB/La	165 [22.92]	21 [11.17]
Anti‐CL IgG	146 [20.28]	20 [10.64]
Anti‐CL IgM	150 [20.83]	27 [14.36]
Anti‐β2GP1‐IgG	151 [20.97]	31 [16.49]

Abbreviations: β₂GPI, β₂ glycoprotein I; CL, cardiolipin; dsDNA, double stranded deoxyribonucleic acid; Ig, immunoglobulin; RNP, ribonucleoprotein; Sm, Smith; SSA/B, Sjögren’s syndrome antigen A/B.